+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Hematology Partnering 2010-2021: Deal Trends, Players and Financials

  • ID: 2208467
  • Report
  • June 2021
  • Region: Global
  • 400 pages
  • CurrentPartnering


  • Abbott Laboratories
  • Biogen
  • Duke University
  • Inserm
  • OMRF
  • Selecta Biosciences
  • MORE
Global Hematology Partnering 2010 to 2021 provides the full collection of Hematology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
  • Trends in Hematology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Hematology partnering agreement structure
  • Hematology partnering contract documents
  • Top Hematology deals by value
  • Most active Hematology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.

The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Hematology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Hematology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Hematology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Hematology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Hematology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Hematology partnering deals by specific Hematology target announced since 2010. The chapter is organized by specific Hematology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Hematology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products.

Report scope

Global Hematology Partnering 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Hematology trends and structure of deals entered into by leading companies worldwide.

Global Hematology Partnering 2010 to 2021 includes:
  • Trends in Hematology dealmaking in the biopharma industry since 2010
  • Analysis of Hematology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Hematology deal contract documents
  • Comprehensive access to over 550 Hematology deal records
  • The leading Hematology deals by value since 2010
  • Most active Hematology dealmakers since 2010
The report includes deals for the following indications: Agranulocytosis, v, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications.

In Global Hematology Partnering 2010 to 2021, available deals and contracts are listed by:
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Hematology Partnering 2010-2021 report provides comprehensive access to available deals and contract documents for over 550 hematology deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
Note: Product cover images may vary from those shown


  • Abbott Laboratories
  • Biogen
  • Duke University
  • Inserm
  • OMRF
  • Selecta Biosciences
  • MORE
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Hematology dealmaking
2.1. Introduction
2.2. Hematology partnering over the years
2.3. Hematology partnering by deal type
2.4. Hematology partnering by industry sector
2.5. Hematology partnering by stage of development
2.6. Hematology partnering by technology type
2.7. Hematology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Hematology partnering
3.1. Introduction
3.2. Disclosed financials terms for Hematology partnering
3.3. Hematology partnering headline values
3.4. Hematology deal upfront payments
3.5. Hematology deal milestone payments
3.6. Hematology royalty rates

Chapter 4 - Leading Hematology deals and dealmakers
4.1. Introduction
4.2. Most active in Hematology partnering
4.3. List of most active dealmakers in Hematology
4.4. Top Hematology deals by value

Chapter 5 - Hematology contract document directory
5.1. Introduction
5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Hematology therapeutic target

Appendix 1 - Directory of Hematology deals by company A-Z 2010 to 2021
Appendix 2 - Directory of Hematology deals by deal type 2010 to 2021
Appendix 3 - Directory of Hematology deals by stage of development 2010 to 2021
Appendix 4 - Directory of Hematology deals by technology type 2010 to 2021
Further reading on dealmaking
Deal type definitions

Table of figures
Figure 1: Hematology partnering since 2010
Figure 2: Hematology partnering by deal type since 2010
Figure 3: Hematology partnering by industry sector since 2010
Figure 4: Hematology partnering by stage of development since 2010
Figure 5: Hematology partnering by technology type since 2010
Figure 6: Hematology partnering by indication since 2010
Figure 7: Hematology deals with a headline value
Figure 8: Hematology deals with upfront payment values
Figure 9: Hematology deals with milestone payment
Figure 10: Hematology deals with royalty rates
Figure 11: Active Hematology dealmaking activity- 2010 to 2021
Figure 12: Top Hematology deals by value since 2010
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Abzena
  • Accord Healthcare
  • Accuscience
  • Acrotech Biopharma
  • Advanced Biological Laboratories
  • AffaMed Therapeutics
  • AkaRx
  • Akebia Therapeutics
  • Akers Biosciences
  • Akron Biotechnology
  • Alchemia
  • Alnylam Pharmaceuticals
  • Alphamedix
  • American society of Hematology
  • Amgen
  • Anthos Therapeutics
  • Antitope
  • Apceth
  • Aplagon
  • ApoPharma
  • Aptevo Therapeutics
  • APT Therapeutics
  • ArcherDX
  • Arch Therapeutics
  • Armaghan Salamat Kish
  • Armetheon
  • Arsia Therapeutics
  • Aruvant Sciences
  • ASKA Pharmaceuticals
  • Aspen Holding
  • AstraZeneca
  • Audaire Health
  • AUT Roche Diagnostics Laboratory
  • AUT University
  • AVL Sofia
  • Banc De Sang I Teixits
  • Baxalta
  • Baxter International
  • Bayer
  • Bayer Healthcare
  • Baylor College of Medicine
  • Beijing Leadman Biochemistry
  • Belgian Red Cross
  • Bicycle Therapeutics
  • Bill and Melinda Gates Foundation
  • Biocept
  • bioCSL
  • Biogen
  • BioMatrix Specialty Pharmacy
  • Biomedical Advanced Research and Development Authority
  • BioMedical Drug Development
  • BioNano Genomics
  • Bioverativ
  • Bleeding Disorders Foundation
  • Blood Bank Of Delmarva
  • Blood Centers of America
  • Blood Systems
  • Bluebird Bio
  • BMG Pharmaceuticals
  • Bonfils Blood Center
  • Boryung Pharmaceutical
  • Bristol-Myers Squibb
  • Bristol-Myers Squibb Foundation
  • C-Bridge Capital
  • Cadila Pharmaceuticals
  • Calbiotech
  • California Institute for Regenerative Medicine
  • Calithera Biosciences
  • Capnia
  • Cardiome Pharma
  • Casebia Therapeutics
  • Case Western Reserve University
  • Catalyst Biosciences
  • CEI
  • Celgene
  • Central California Blood Center
  • Cerus
  • Cesca Therapeutics
  • Children's Hospital of Philadelphia
  • Children's Minnesota
  • China Biologic Products
  • China Cord Blood
  • Cincinnati Children’s Hospital Medical Center
  • CJ Corp
  • Clinigen
  • CMC Biologics
  • Comercializadora BioRenal
  • Cord Blood Registry
  • Cordlife
  • CRISPR Therapeutics
  • CSL Behring
  • CSL Plasma
  • Cytonet
  • CytoSorbents
  • Daiichi Sankyo
  • DaVita
  • Defense Advanced Research Projects Agency
  • Department of Health and Human Services
  • Dimension Therapeutics
  • Dova Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Dr Franz Kohler Chemie
  • Duke University
  • Eagle Pharmaceuticals
  • EMD Serono
  • Emergent BioSolutions
  • Emirates Gastroenterology & Hepatology Society
  • EpiDestiny
  • ERBA Diagnostics
  • Ergomed
  • Esperion Therapeutics
  • European Medicines Agency
  • Evonik Industries
  • Evotec
  • Expression Therapeutics
  • Fibriant
  • Fibrogen
  • Fondazione Telethon
  • Fortis Healthcare
  • Fresenius Kabi Pharmaceuticals
  • Fresenius Medical Care
  • Gamida Cell
  • Gateway Hemophilia Association
  • GC Pharma
  • GE Healthcare
  • Gencia Biotech
  • Genexine
  • Genoptix
  • GenTegra
  • GenVec
  • Genzyme
  • Global Blood Disorder Foundation
  • GNYHA Services
  • Golden Meditech
  • Government Scientific Source
  • Greater New York Hospital Association
  • Grifols
  • Haemonetics Corporation
  • HanAll Pharmaceuticals
  • Harvard Medical School
  • Healthcare Royalty Partners
  • Helsinn Healthcare
  • HemaCare
  • Hemophilia Foundation of Southern California
  • Henry Schein
  • Heska
  • Hologic
  • Homology Medicines
  • Horiba
  • Horizon Pharma plc
  • Immucor
  • Immune Deficiency Foundation
  • Incyte
  • Inserm
  • Inserm Transfert
  • Institute for Genome Statistics and Bioinformatics
  • Institute of Human Genetics
  • Instrumentation Laboratory
  • Intrinsic LifeSciences
  • inviCRO
  • Ionis Pharmaceuticals
  • Irish Haemophilia Society
  • Israeli Ministry of Industry and Commerce
  • Israeli National Authority for Technological Innovation
  • Jazz Pharmaceuticals
  • Karolinska University Hospital
  • Kiadis Pharma
  • Kurin
  • Kyoto University
  • LabPro
  • La Jolla Pharmaceutical
  • Lee's Pharmaceutical
  • LFB Biotechnologies
  • LifeHealth
  • Ligand Pharmaceuticals
  • Lonza
  • Loop Medical
  • Mallinckrodt Pharmaceuticals
  • Massachusetts Institute of Technology
  • Masterlab
  • Masters Speciality Pharma
  • Mayo Clinic
  • Medgenics
  • Medial
  • Medica
  • MedImmune
  • Meditrade
  • Medline Industries
  • Menarini
  • Merus Labs International
  • Metabasis Therapeutics
  • MicroHealth
  • Miraca Life Sciences
  • Mitsubishi Tanabe Pharma
  • Moberg Pharma
  • National Center for Advancing Translational Sciences (NCATS)
  • National Heart
  • Lung and Blood Institute
  • National Hemophilia Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • National Transfusiology Center
  • NCPC GeneTech
  • New York Blood Center
  • Novartis
  • NovImmune
  • Novo Nordisk
  • Nxstage Medical
  • Octapharma
  • OMRF
  • OrSense
  • Ortho-Clinical Diagnostics
  • Otsuka
  • Oxford BioMedica
  • Palex Medical
  • Pan American Cancer Treatment Centers
  • PathoQuest
  • Pathway Diagnostics
  • PBM Capital Group
  • Peking University
  • Pfenex
  • Pfizer
  • Pfizer Japan
  • Pharmacosmos
  • PhaseBio Pharmaceuticals
  • Pieris
  • Portola Pharmaceuticals
  • Premier Inc
  • Promethera Biosciences
  • Prophylix Pharma
  • Protagonist Therapeutics
  • Provepharm
  • Qiagen
  • Quotient Bioscience
  • Regen BioPharma
  • Research Center for Molecular Medicine of the Austrian Academy of Sciences
  • rEVO Biologics
  • Rhode Island Blood Center
  • Rigel Pharmaceuticals
  • Roche Diagnostics
  • Rockwell Medical
  • Roivant Sciences
  • Romark Laboratories
  • Royal College of Surgeons (Ireland)
  • Royalty Pharma
  • RPRD Diagnostics
  • Sage Bionetworks
  • Salix Pharmaceuticals
  • Samsung Bioepis
  • Sangamo BioSciences
  • Sanofi
  • San Raffaele Telethon Institute for Gene Therapy
  • Saol Therapeutics
  • Sayre Therapeutics
  • SciClone Pharmaceuticals
  • Science Foundation Ireland
  • Scil Animal Care
  • Sekisui Medical
  • Selecta Biosciences
  • Selexis
  • Seventh Sense Biosystems
  • Shanghai RAAS Blood Products
  • Shionogi
  • Shire Laboratories
  • Shire Pharmaceuticals
  • Sidero Bioscience
  • Sigilon Therapeutics
  • Small Business Innovation Research
  • Sophia Genetics
  • Spark Therapeutics
  • Spectrum Pharmaceuticals
  • Spindial
  • SQI Diagnostics
  • Stanford University
  • Strides Arcolab
  • SunCoast Blood Bank (SCBB)
  • Supernus Pharmaceuticals
  • Swedish Orphan Biovitrum
  • Swiss Red Cross
  • Swiss Transfusion SRC
  • Sysmex America
  • Takeda Pharmaceutical
  • Targacept
  • Tasly Pharmaceuticals
  • Tasso
  • Tennessee Hemophilia
  • Terumo
  • Thalassaemia International Federation
  • The Medicines Company
  • Thermo Fisher Scientific
  • TNO Pharma
  • Tokra Medikal
  • Topas Therapeutics
  • Turgut Ilaclari
  • UCB
  • Uniformed Services University of the Health Sciences
  • University College Cork
  • University of Bonn
  • University of Maryland Baltimore
  • University of Pittsburgh
  • Unyts
  • US Bioservices
  • Velesco
  • Velocity Pharmaceutical Development
  • Verax Biomedical
  • Versiti Blood Research Institute
  • Vertex Pharmaceuticals
  • Vifor Pharma
  • Viking Therapeutics
  • Vitesse Biologics
  • Wanbang Biopharmaceuticals
  • Washington University in St Louis
  • Worcester Polytechnic Institute (WPI)
  • Xenetic Biosciences
Note: Product cover images may vary from those shown
  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.